Fundraising FoxXeno Biosciences
Somerville, US · Founded 2015 · Delaware corporation · 3 known investors
Find your way into Xeno Biosciences
Sign up to see every warm intro you have to Xeno Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Xeno Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
DK
Dennis KimPresident and CEODennis Kim holds an M.D. and MBA from UC San Diego and has over 15 years of experience in biopharmaceutical and medical device executive roles, including Chief Medical Officer positions at CymaBay, Emerald Biosciences, and Zafgen, and senior leadership at Orexigen Therapeutics, EnteroMedics, and Amylin Pharmaceuticals where he led clinical development for Byetta. He is currently President and CEO of Xeno Biosciences, a biotechnology company developing obesity therapeutics.
MK
Michael KoerisNamed on SEC filing
HC
Hasan CelikerNamed on SEC filing
DB
David BenoNamed on SEC filing
Investors · 3
Bantam Grouplisted by Bantam GroupWestwood
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$12.1M disclosed across 4 rounds · 2018–2022
▶$1.5MraisedJan 2023 · 64 investors · BiotechnologyRule 506(b)
▶$1.5MraisedJan 2023 · 64 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BenoExecutive Officer, Director
- Jeffrey ArnoldDirector
- Michael KoerisDirector
- Tom HughesDirector
- Stan RoseDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.4MraisedAug 2021 · 133 investors · BiotechnologyRule 506(b)
▶$9.4MraisedAug 2021 · 133 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey ArnoldDirector
- Michael KoerisDirector
- Stan RoseDirector
- David BenoExecutive Officer, Director
- Offering amount
- $9.9M
- Amount sold
- $9.4M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$720KraisedFeb 2019 · 21 investors · BiotechnologyRule 506(b)
▶$720KraisedFeb 2019 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael KoerisDirector
- Hasan CelikerExecutive Officer, Director
- David BenoDirector
- Offering amount
- $1.6M
- Amount sold
- $720K
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$450KraisedAug 2018 · 20 investors · BiotechnologyRule 506(b)
▶$450KraisedAug 2018 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael KoerisDirector
- Hasan CelikerExecutive Officer, Director
- David BenoDirector
- Offering amount
- $450K
- Amount sold
- $450K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Xeno Biosciences's investors?
- Xeno Biosciences's investors include Bantam Group, Boston Harbor Angels, Keiretsu Forum.
- How much funding has Xeno Biosciences raised?
- Xeno Biosciences has disclosed $12.1M raised across 4 rounds.
- Where is Xeno Biosciences headquartered?
- Xeno Biosciences is headquartered in Somerville, US.